← Leaderboards
Raymond Yeung
University Of Washington
$9,332,953
Attributed
$11,177,633
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,677,633 · 6
FDA$2,500,000 · 1
By mechanism
R01$7,059,272 · 3
U01$3,289,531 · 2
R21$828,830 · 2
Top collaborators
- Shao-En Ong2 shared
- Wei Wei2 shared
- Taran Singh Gujral1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Stephen Mark Schwartz$17,996,380
- Pamela J Fink$12,911,564
- Shao-En Ong$5,152,746
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeTumor Suppressor GenesTumorMalignant NeoplasmsPathway InteractionsLinkCellsPlayAffectNeoplasm /Cancer GeneticsPathogenesisTuberous SclerosisNeoplastic ProcessMutantTsc2 GeneSignal TransductionRenal Cell CarcinomaResearch StudyLaboratory RatProteinsTumorigenesisCell PhysiologyCell TypeDisease /Disorder Model
Grant awards (29)
MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.$388,418
U01 · FY2025 · CA · contact PI
Proteomic signatures to predict drug response in cancer$181,741
R21 · FY2025 · CA
MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.$401,113
U01 · FY2024 · CA · contact PI
Proteomic signatures to predict drug response in cancer$218,089
R21 · FY2024 · CA
SMARTCORE Technology: Using AI and Patient Tissue to Identify Potential Cancer Therapies for Ultra-rare Cancers$2,500,000
U01 · FY2023 · FD
Pathogenesis of TSC2-Related Tumors$344,442
R01 · FY2012 · CA · contact PI
Pathogenesis of TSC2-Related Tumors$344,442
R01 · FY2011 · CA · contact PI
Pathogenesis of TSC2-Related Tumors$355,095
R01 · FY2010 · CA · contact PI
The Role of TSC2 in EMT: A Model for LAM$234,000
R21 · FY2010 · HL · contact PI
Pathogenesis of TSC2-Related Tumors$355,095
R01 · FY2009 · CA · contact PI
The Role of TSC2 in EMT: A Model for LAM$195,000
R21 · FY2009 · HL · contact PI
Pathogenesis of TSC2-Related Tumors$355,095
R01 · FY2008 · CA · contact PI
In Vivo Studies of TSC-Related Tumorigenesis$294,676
R01 · FY2008 · CA · contact PI
In Vivo Studies of TSC-Related Tumorigenesis$294,676
R01 · FY2007 · CA · contact PI
Pathogenesis of TSC2-Related Tumors$69,289
R01 · FY2007 · CA · contact PI
Pathogenesis of TSC2-Related Tumors$335,028
R01 · FY2006 · CA · contact PI
In Vivo Studies of TSC-Related Tumorigenesis$303,477
R01 · FY2006 · CA · contact PI
Pathogenesis of TSC2-Related Tumors$343,091
R01 · FY2005 · CA
In Vivo Studies of TSC-Related Tumorigenesis$310,780
R01 · FY2005 · CA
CANCER SUSCEPTIBILITY IN AN ANIMAL MODEL$346,431
R01 · FY2004 · CA
Pathogenesis of TSC2-Related Tumors$343,091
R01 · FY2004 · CA
In Vivo Studies of TSC-Related Tumorigenesis$310,780
R01 · FY2004 · CA
Pathogenesis of TSC2-Related Tumors$343,091
R01 · FY2003 · CA
CANCER SUSCEPTIBILITY IN AN ANIMAL MODEL$338,755
R01 · FY2003 · CA
CANCER SUSCEPTIBILITY IN AN ANIMAL MODEL$331,302
R01 · FY2002 · CA
PATHOGENESIS OF TSCE-RELATED TUMORS IN THE EKER RAT$343,996
R01 · FY2001 · CA
CANCER SUSCEPTIBILITY IN AN ANIMAL MODEL$324,058
R01 · FY2001 · CA
CANCER SUSCEPTIBILITY IN AN ANIMAL MODEL$336,522
R01 · FY2000 · CA
PATHOGENESIS OF TSCE-RELATED TUMORS IN THE EKER RAT$336,060
R01 · FY2000 · CA